Trials / Completed
CompletedNCT02759419
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
An Open-label, Multi-national, Multi-center, Single-arm, Uncontrolled, Long-term Extension Study of Orally Administered Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH) Who Received Riociguat in a Bayer Clinical Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521/ Riociguat / Adempas® who are currently or recently treated in these trials until lack of patient benefit as assessed by investigator, or commercial availability and reimbursement.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adempas (Riociguat, BAY63-2521) | 0.5 to 2.5 mg in 0.5 mg increments (according to individual adapted optimal dose determined in originating study) administered three times daily (tid) |
Timeline
- Start date
- 2016-06-16
- Primary completion
- 2025-09-15
- Completion
- 2025-09-15
- First posted
- 2016-05-03
- Last updated
- 2025-10-03
Locations
9 sites across 2 countries: France, South Korea
Source: ClinicalTrials.gov record NCT02759419. Inclusion in this directory is not an endorsement.